229 related articles for article (PubMed ID: 28849250)
1. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.
Sanchez Spitman AB; Moes DJAR; Gelderblom H; Dezentje VO; Swen JJ; Guchelaar HJ
Eur J Clin Pharmacol; 2017 Dec; 73(12):1589-1598. PubMed ID: 28849250
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.
Antunes MV; Timm TA; de Oliveira V; Staudt DE; Raymundo S; Gössling G; Biazús JV; Cavalheiro JA; Rosa DD; Wallemacq P; Haufroid V; Linden R; Schwartsmann G
Ther Drug Monit; 2015 Dec; 37(6):733-44. PubMed ID: 25853922
[TBL] [Abstract][Full Text] [Related]
3. Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients.
Fernández-Santander A; Gaibar M; Novillo A; Romero-Lorca A; Rubio M; Chicharro LM; Tejerina A; Bandrés F
PLoS One; 2013; 8(7):e70183. PubMed ID: 23922954
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes.
Mugundu GM; Sallans L; Guo Y; Shaughnessy EA; Desai PB
Drug Metab Dispos; 2012 Feb; 40(2):389-96. PubMed ID: 22096084
[TBL] [Abstract][Full Text] [Related]
5. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
[TBL] [Abstract][Full Text] [Related]
6. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.
Teft WA; Gong IY; Dingle B; Potvin K; Younus J; Vandenberg TA; Brackstone M; Perera FE; Choi YH; Zou G; Legan RM; Tirona RG; Kim RB
Breast Cancer Res Treat; 2013 May; 139(1):95-105. PubMed ID: 23580071
[TBL] [Abstract][Full Text] [Related]
7. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.
Lim JS; Chen XA; Singh O; Yap YS; Ng RC; Wong NS; Wong M; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2011 May; 71(5):737-50. PubMed ID: 21480951
[TBL] [Abstract][Full Text] [Related]
9. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer.
Souwer ETD; Sanchez-Spitman A; Moes DJAR; Gelderblom H; Swen JJ; Portielje JEA; Guchelaar HJ; van Gelder T
Breast Cancer Res Treat; 2023 Jun; 199(3):471-478. PubMed ID: 37067610
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
Goetz MP; Rae JM; Suman VJ; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Flockhart DA; Desta Z; Perez EA; Ingle JN
J Clin Oncol; 2005 Dec; 23(36):9312-8. PubMed ID: 16361630
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.
Desta Z; Ward BA; Soukhova NV; Flockhart DA
J Pharmacol Exp Ther; 2004 Sep; 310(3):1062-75. PubMed ID: 15159443
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22.
Baxter SD; Teft WA; Choi YH; Winquist E; Kim RB
Breast Cancer Res Treat; 2014 Jun; 145(2):419-28. PubMed ID: 24744093
[TBL] [Abstract][Full Text] [Related]
14. Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.
Powers JL; Buys SS; Fletcher D; Melis R; Johnson-Davis KL; Lyon E; Malmberg EM; McMillin GA
J Clin Pharmacol; 2016 Dec; 56(12):1570-1581. PubMed ID: 27198207
[TBL] [Abstract][Full Text] [Related]
15. Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score.
Wu AH; Lorizio W; Tchu S; Lynch K; Gerona R; Ji W; Ruan W; Ruddy KJ; Desantis SD; Burstein HJ; Ziv E
Breast Cancer Res Treat; 2012 Jun; 133(2):677-83. PubMed ID: 22294487
[TBL] [Abstract][Full Text] [Related]
16. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.
ter Heine R; Binkhorst L; de Graan AJ; de Bruijn P; Beijnen JH; Mathijssen RH; Huitema AD
Br J Clin Pharmacol; 2014 Sep; 78(3):572-86. PubMed ID: 24697814
[TBL] [Abstract][Full Text] [Related]
18. CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen.
Antunes MV; de Oliveira V; Raymundo S; Staudt DE; Gössling G; Biazús JV; Cavalheiro JA; Rosa DD; Mathy G; Wallemacq P; Linden R; Schwartsmann G; Haufroid V
Pharmacogenomics; 2015; 16(6):601-17. PubMed ID: 25893704
[TBL] [Abstract][Full Text] [Related]
19. Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.
Bissada JE; Truong V; Abouda AA; Wines KJ; Crouch RD; Jackson KD
Drug Metab Dispos; 2019 Nov; 47(11):1257-1269. PubMed ID: 31492693
[TBL] [Abstract][Full Text] [Related]
20. Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.
Bruckmueller H; Werk AN; Renders L; Feldkamp T; Tepel M; Borst C; Caliebe A; Kunzendorf U; Cascorbi I
Ther Drug Monit; 2015 Jun; 37(3):288-95. PubMed ID: 25271728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
